The role of immunotherapy in the management of patients with renal cell carcinoma and brain metastases

Jaleh Fallah¹, Manmeet S. Ahluwalia¹²

¹Taussig Cancer Institute, ²Burkhardt Brain Tumor and Neuro-Oncology Center, Cleveland Clinic, Cleveland Ohio, OH, USA

Correspondence to: Manmeet S. Ahluwalia, MD, FACP. Professor, Department of Medicine, Burkhardt Brain Tumor and Neuro-Oncology Center, Neurological Institute, Cleveland Clinic, 9500 Euclid Ave., S73, Cleveland, OH, 44195, USA. Email: ahluwam@ccf.org.

Provenance: This is an invited article commissioned by the Section Editor Dr. Xiao Li (Department of Urology, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing Medical University Affiliated Cancer Hospital, Nanjing, China).


Submitted Sep 22, 2019. Accepted for publication Sep 30, 2019.

doi: 10.21037/atm.2019.10.31

View this article at: http://dx.doi.org/10.21037/atm.2019.10.31

Patients with metastatic renal cell carcinoma (mRCC) who have metastases to the brain have poor prognosis and median overall survival (OS) of 6 to 10 months (1,2). Local treatments such as surgical resection, stereotactic radiosurgery (SRS) and whole brain radiation therapy (WBRT) are the mainstay of treatment in these patients. The decision to choose one of these approaches depends on the number, size and location of the brain lesions, presence or absence of symptoms and the level of expertise available in the treating facility. Surgical resection is generally performed in patients with a solitary and easily accessible brain lesion. WBRT is mostly utilized in the treatment of patients with numerous brain metastases (mostly for >10 lesions) and SRS is the treatment of choice in patients with limited brain metastases (up to 10 lesions). The rate of local control with SRS is more than 90% (3,4) and overall, it has been found to be safe and well-tolerated by patients.

Recent clinical trials in patients with melanoma have shown efficacy of checkpoint inhibitors in the treatment of brain metastases. In phase II clinical trials of pembrolizumab or ipilimumab in patients with melanoma with asymptomatic previously untreated melanoma, the objective response rate (ORR) was 22–26% (Table 1). Combination of ipilimumab plus nivolumab was studied in two phase II clinical trials in patients with melanoma with asymptomatic previously untreated brain metastases and resulted in 46–57% intracranial response, including 17–26% intracranial complete response (5-9).

Using checkpoint inhibitors as monotherapy or in combination with chemotherapy in patients with metastatic non-small cell lung cancer (NSCLC) has shown efficacy in management of brain metastases. In a phase II clinical trial, 18 patients with NSCLC with asymptomatic brain metastases previously untreated or progressing on local treatment were treated with pembrolizumab alone and had intracranial response rate 33% (9). Most of the patients with NSCLC with brain metastases who responded to treatment had a durable response (13). KEYNOTE-189 is a randomized double-blinded phase III clinical trial of pembrolizumab plus chemotherapy versus chemotherapy alone in patients with metastatic non-squamous NSCLC. Among 606 patients enrolled into this clinical trial, 108 patients had brain metastases. The results of the study showed that patients with NSCLC with brain metastases who received combination of pembrolizumab plus chemotherapy has significantly better survival outcomes compared to those who were treated with chemotherapy only, hazard ratio (HR) for OS 0.36, HR for progression-free survival (PFS) 0.42 (10).

Emergence of vascular endothelial growth factor (VEGF) inhibitors and checkpoint inhibitors has revolutionized the treatment of mRCC. Phase III clinical trials of checkpoint inhibitors in patients with mRCC resulted in durable responses and improved survival outcomes in frontline and second line settings. CheckMate-025 clinical trial demonstrated significant improvement in ORR and OS in patients with mRCC treated with nivolumab compared with everolimus, after progression on a previous anti-
Table 1 The efficacy of immunotherapy in management of brain metastases

<table>
<thead>
<tr>
<th>Primary tumor</th>
<th>Study phase</th>
<th>Study population</th>
<th>Study size</th>
<th>Treatment</th>
<th>Major treatment outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Melanoma</td>
<td>II</td>
<td>Patients with melanoma with brain metastases</td>
<td>72</td>
<td>Ipilimumab (5)</td>
<td>Intracranial disease control rate: 24% in cohort A, 10% in cohort B</td>
</tr>
<tr>
<td></td>
<td>II</td>
<td>Patients with melanoma with asymptomatic untreated brain metastases</td>
<td>23</td>
<td>Pembrolizumab (6)</td>
<td>Intracranial ORR 26%</td>
</tr>
<tr>
<td></td>
<td>II</td>
<td>Patients with melanoma with untreated asymptomatic brain metastases</td>
<td>94</td>
<td>Nivolumab plus ipilimumab (7)</td>
<td>Intracranial ORR 57%, (Intracranial CR 26%)</td>
</tr>
<tr>
<td></td>
<td>II</td>
<td>Patients with melanoma with untreated asymptomatic brain metastases</td>
<td>63</td>
<td>Cohort A (n=36): nivolumab plus ipilimumab</td>
<td>Intracranial ORR: 46% in cohort A, 20% in cohort B</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cohort B (n=27): nivolumab (8)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Melanoma &amp; NSCLC</td>
<td>II</td>
<td>Patients with melanoma or NSCLC with asymptomatic untreated brain metastases</td>
<td>36</td>
<td>Pembrolizumab (9)</td>
<td>Intracranial ORR: 22% in patients with melanoma and 33% in patients with NSCLC</td>
</tr>
<tr>
<td>NSCLC</td>
<td>III</td>
<td>Patients with metastatic non-squamous NSCLC brain metastases without sensitizing EGFR or ALK mutations</td>
<td>108</td>
<td>Platinum-based chemotherapy plus either pembrolizumab or placebo (10)</td>
<td>Patients treated with pembrolizumab plus chemotherapy had better survival outcomes</td>
</tr>
<tr>
<td>RCC</td>
<td>IIIb/IV</td>
<td>Patients with previously untreated (no radiation, not on any steroids) metastatic RCC (any histology) with asymptomatic brain metastases</td>
<td>28</td>
<td>Nivolumab and ipilimumab (11)</td>
<td>Overall ORR: 28%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>PFS 9.0 months</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>OS not reached</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Both patients with a target brain lesion had response to treatment</td>
</tr>
<tr>
<td></td>
<td>II</td>
<td>Patients with metastatic ccRCC who had disease progression on anti-VEGF therapies</td>
<td>73</td>
<td>Nivolumab (12)</td>
<td>Intracranial ORR in cohort A: 12%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>OS at 12 months: 67% in cohort A, 59% in cohort B</td>
</tr>
</tbody>
</table>

VEGF treatment (14). The CheckMate-214 study showed significantly better ORR and longer OS with ipilimumab plus nivolumab followed by maintenance nivolumab compared to sunitinib (OS HR 0.63) (15).

The combination of checkpoint inhibitors and VEGF-TKIs were studied in two phase III clinical trials for first line treatment of mRCC. In KEYNOTE-426, patients with previously untreated mRCC who received the combination of pembrolizumab plus axitinib had significantly better survival outcomes compared to those who were treated with sunitinib [HR for OS 0.53, 95% confidence interval (CI): 0.38–0.74] (16). In JAVELIN Renal 101, the combination of avelumab plus axitinib resulted in significantly better PFS compared to sunitinib in patients with previously untreated mRCC (HR for PFS 0.69, 95% CI: 0.56–0.84) (17). Based on the results of these clinical trials, the combination of ipilimumab plus nivolumab, pembrolizumab plus axitinib, and avelumab plus axitinib have been approved by the Food...
and Drug Administration (FDA) for treatment of mRCC in the frontline setting. However, most of the pivotal clinical trials in patients with mRCC, excluded patients with brain metastases and those which included these patients did not report the outcomes in this subgroup of patients.

Two recent clinical trials have studied the safety and efficacy of checkpoint inhibitors in patients with mRCC with brain metastases and showed that the treatment with nivolumab as monotherapy or in combination with ipilimumab in patients with mRCC brain metastases is safe (11,12).

CheckMate-920 is a phase IIIb/VI clinical trial to study the safety and efficacy of the combination of ipilimumab plus nivolumab followed by maintenance nivolumab in previously untreated mRCC. The cohort 3 of this clinical trial enrolled patients with mRCC of any histology who had asymptomatic brain metastases. Among 28 patients who were enrolled in the brain metastases cohort, 21 patients had non-target (smaller than 10 mm or previously irradiated) brain lesions. The minimum follow up at the time of interim analysis was 6.5 months at which point, 2 patients had significant decrease in size of the target brain lesion and 5 patients (17%) had progression of non-target brain lesions or developed new brain metastases (11).

The GETUG-AFU 26 NIVOREN Brain Metastases study is a phase II clinical trial which enrolled patients with mRCC brain metastases who had disease progression on at least one prior anti-VEGF therapy. Patients with asymptomatic previously untreated target brain lesions were included in cohort A (39 patients) and those with previously treated target brain metastases were included in cohort B (34 patients). In Nivoren-26 clinical trial, the ORR was 19% which was lower than the ORR 25% in CheckMate-025. The worse outcomes in Nivoren-26 can be due to the previously heavily treated patient population which are less likely to respond to treatment. In Nivoren-26 study, 31% of the patients had 2 prior anti-VEGF therapies and 31% of the patients were previously treated with at least 3 anti-VEGF therapy, whereas in CheckMate-025 study, 72% of the patients had only one prior anti-VEGF therapy. Moreover, RCC cells which invade into the brain may be less responsive to immunotherapy, which might have led to worse outcomes in patients in the Nivoren-26 study compared to CheckMate-025 study which excluded patients with brain metastases (12,14).

In the GETUG-AFU 26 NIVOREN Brain Metastases study, the intracranial ORR in cohort A (primary endpoint) was 12% which was only seen in patients with a solitary brain lesion smaller than 10 mm. The intracranial median PFS in cohort A and cohort B were 2.7 and 4.8 months, respectively. The 12-month OS was 67% in cohort A and 59% in cohort B. More than half of the patients (51%) in cohort A needed treatment with corticosteroids compared to 27% of the patients in cohort B. Subsequent local therapy (surgical resection or radiation therapy) was needed in 72% of the patients in cohort A and 21% of the patients in cohort B (12).

Checkpoint inhibitors treat brain metastases by activating the peripheral T-cells which circulate in the blood and access the brain metastases. However, systemic treatment with checkpoint inhibitors is not adequate to control the intracranial metastatic disease. Previous studies of anti-VEGF therapy and checkpoint inhibitors in patients with mRCC brain metastases showed improved OS despite lack of local control which suggests that the survival benefit with systemic therapy was mainly due to control of the extracranial disease (18,19).

Using concurrent immunotherapy with radiation therapy can yield a synergistic effect against tumor cells. One of the mechanisms that malignant cells evade the immune system is by decreasing the expression of the tumor antigens. Radiation therapy to solid tumors results in necrosis of the tumor tissue and release of tumor antigens into the blood which increases the exposure of the immune system into the tumor antigens. PEMBRO-RT is a phase II clinical trial which randomized 72 patients with metastatic NSCLC to receive the combination of pembrolizumab plus SBRT or pembrolizumab only. No increase in toxicity was observed in the combination arm. The ORR at 12 weeks was significantly better in patients treated with combination therapy (36%) compared with those treated with pembrolizumab monotherapy (18%). However, there was no statistically significant difference in PFS and OS between the treatment arms. A subgroup analysis showed that the clinical benefit from addition of RT to pembrolizumab was mainly seen among patients with negative PD-L1 expression (20). Several clinical trials are currently investigating the abscopal effect with combination of RT and immunotherapy in patients with Hodgkin’s lymphoma (NCT03480334), melanoma (NCT03354962), esophageal and gastric cancer (NCT02830594), and carcinoma of unknown primary (NCT03396471).

Retrospective studies suggest a synergy between SRS of brain lesions and systemic treatment with checkpoint inhibitors. In a retrospective study of 260 patients with melanoma, NSCLC and RCC with brain...
metastases, patients treated with stereotactic radiosurgery-stereotactic radiation therapy (SRS-SRT) and concurrent immunotherapy (within 2 weeks of radiation) had significantly longer OS compared to those who were treated with SRS-SRT only (HR 2.69, P 0.002) or non-concurrent immunotherapy (HR 2.40, P 0.006). Moreover, there was a significant decrease in incidence of new brain metastases in patients treated with concurrent SRS plus checkpoint inhibitors (odds ratio 0.33, P=0.045) (21). Several ongoing clinical trials are investigating the safety and efficacy of the combination of SRS plus checkpoint inhibitors in patients with melanoma and NSCLC with brain metastases (NCT03340129, NCT02858869).

Delay in local control of brain lesions is another limitation of systemic treatment for management of brain metastases. In patients with mRCC, the median time to response to checkpoint inhibitor or anti-VEGF therapy is approximately 3 months (14-17). Therefore, in patients with brain metastases, particularly those with symptomatic and active metastatic lesions, rapid control of brain metastases by traditional approaches such as SRS or surgery is necessary.

For management of patients with mRCC and brain metastases, we recommend a multi-modality approach, using a combination of local therapies such as SRS to achieve local control of the intracranial disease, plus systemic treatment to control the intracranial and extracranial disease. Use of local treatments such as SRS in treatment of mRCC is particularly needed in patients with multiple, large or symptomatic brain lesions. Future studies need to assess the intracranial efficacy of the combination of anti-VEGF therapy plus immunotherapy in patients with mRCC, as well as the safety and efficacy of the combination of the systemic treatments with radiation therapy in these patients, and the interval and sequence of local and systemic treatments for management of patients with RCC and brain metastases.

Acknowledgments

None.

Footnote

Conflicts of Interest: Manmeet Ahluwalia: Receipt of grants/research supports: Astrazeneca, Abbvie, BMS, Bayer, Incyte, Pharmacyciles, Novocure, Merek; Receipt of honoraria or consultation fees: Elsevier, Wiley, Astrazeneca, Abbvie, VBI Vaccines, Flatiron, Varian Medical Systems, Prime Education, Bayer, karyopharm, Tocagen, Forma therapeutics; Stock shareholder: Doctible, Mimivax. The other author has no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

References


Cite this article as: Fallah J, Ahluwalia MS. The role of immunotherapy in the management of patients with renal cell carcinoma and brain metastases. Ann Transl Med 2019. doi: 10.21037/atm.2019.10.31